Valeant Suffers Q2 Loss With a Boost in Revenues
Thursday, July 23, 2015
Source: Rochester Business Journal
Bausch & Lomb Inc. parent Valeant Pharmaceuticals International Inc. on Thursday reported a net loss of $53 million, or 15 cents a diluted share. Eye-care company sales accounted for $243.1 million of the Quebec-based Valeant’s $2.7 billion in second-quarter revenues.